Kyle Wegner is a dedicated Study Director at Labcorp Drug Development, located in Madison, Wisconsin, where he plays a pivotal role in advancing nonclinical toxicology studies aimed at securing international regulatory approvals. With a robust background in molecular and cellular biology, Kyle expertly oversees the...
Kyle Wegner is a dedicated Study Director at Labcorp Drug Development, located in Madison, Wisconsin, where he plays a pivotal role in advancing nonclinical toxicology studies aimed at securing international regulatory approvals. With a robust background in molecular and cellular biology, Kyle expertly oversees the design, execution, and reporting of studies that are critical for FDA, CFDA, and OECD submissions. His expertise in genetic mouse models and urinary physiology allows him to delve into the complexities of the fetal basis of adult disease, providing valuable insights that inform drug safety and efficacy.
At Labcorp, a leading global contract research organization (CRO), Kyle is at the forefront of innovative drug development strategies, collaborating with multidisciplinary teams to address pressing global healthcare challenges. His proficiency in advanced techniques such as confocal microscopy, immunohistochemistry, and reverse transcription polymerase chain reaction (RT-PCR) enables him to generate high-quality data that supports regulatory submissions and enhances the understanding of toxicological impacts.
Kyle is currently engaged in several key projects that focus on the safety assessment of new therapeutics, utilizing his skills in data management and analysis to ensure that findings are robust and reliable. He is passionate about fostering collaborations that bring diverse perspectives to the table, recognizing that the complexities of modern healthcare require a collective approach. If you are interested in discussing innovative solutions or exploring potential partnerships in drug development, Kyle welcomes connections from industry peers and stakeholders alike.
